Pharmesis International (SGX:BFK) completed the acquisition of the remaining 19% stake it did not own in Sichuan Longlife Pharmaceutical, a filing with the Singapore Exchange said on Monday.
Following the acquisition, Sichuan has become a wholly owned subsidiary of the company.
Pharmesis first announced the deal on Sept. 23, agreeing to acquire the balance stake for 2.8 million yuan.
Shares of Pharmesis surged over 14% in recent trading.
Price (SGD): S$0.20, Change: S$+0.025, Percent Change: +14.29%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。